A novel human foamy virus mediated gene transfer of GAD67 reduces neuropathic pain following spinal cord injury.
Neurosci Lett
; 432(1): 13-8, 2008 Feb 13.
Article
en En
| MEDLINE
| ID: mdl-18180106
Neuropathic pain is a long-lasting clinical problem that is often refractory to medical management. Gene transfer of specific genes for therapeutic benefit offers a novel approach to the treatment of neuropathic pain. In this study, we tested whether the transfer of the glutamic acid decarboxylase (GAD) gene to dorsal root ganglion (DRG) cells would attenuate below-injury level central neuropathic pain after spinal cord injury (SCI) by using a novel human foamy virus (HFV) vector to achieve release of gamma-aminobutyric acid (GABA). Subcutaneous inoculation of a replication-defective HFV vector, which expresses GAD (vector rdvGAD67) for 7days after T13 spinal cord hemisection, reversed mechanical allodynia and thermal hyperalgesia evoked by SCI. The antiallodynic effect lasted 6 weeks and was reestablished by reinoculation. We also found that subcutaneous inoculation of rdvGAD67 resulted in enhanced production of GAD and tonical GABA release from transduced DRG neurons. These results suggest that HFV-mediated gene transfer to DRG could be employed to treat below-injury level central neuropathic pain after incomplete SCI.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Traumatismos de la Médula Espinal
/
Terapia Genética
/
Spumavirus
/
Glutamato Descarboxilasa
/
Neuralgia
Tipo de estudio:
Etiology_studies
Límite:
Animals
Idioma:
En
Revista:
Neurosci Lett
Año:
2008
Tipo del documento:
Article
Pais de publicación:
Irlanda